Structural Bioinformatics, Inc. (SBI) is a world leader in proteomics-driven drug discovery – the large-scale generation and use of protein structural information to accelerate the discovery and optimization processes.

SBI’s Genes to Leads technology, employing SBI’s proprietary DynaPharm and CombiLib technologies, offers a truly practical response to the wealth of new drug targets emerging from genomic sequencing efforts around the world for the human genome and the genomes of hundreds of infectious disease agents. Our technology reliably produces drug leads – in 60-120 days - starting with the sequence alone, with an efficiency that is more than 1,000-fold greater than state-of-the-art high throughput screening (HTS). The efficiencies in speed and cost are the direct result of the use of our underlying proprietary computational proteomics platform that allows us to generate X-ray quality protein structures at a fraction of the cost and time.^®®®

We further leverage our proteomics, pattern recognition, and data fusion technologies through our structural database products:

• the ProMax drug target database - containing thousands of proprietary drug target and “anti-target” structures in more than 470 structural families; ™
• the Variome family of structural polymorphism databases containing tens of thousands of unique polymorphism structures - providing pharmacogenomics insights early on in the drug discovery process; and ™
• StructureBank – a universal repository and enterprise-wide solution for large-scale storage and comparative analysis of protein structures.™

The Company’s extensive supercomputer, drug discovery laboratory, and office facilities are headquartered in San Diego, CA, with operational subsidiaries in Hørsholm, Denmark, Cambridge, MA, and Washington, DC. SBI’s 100 employees include more than 50 Ph.D.s in a diverse range of disciplines including physics and biophysics, mathematics, medicinal and analytical chemistry, molecular and cell biology, biochemistry, and X-ray crystallography.

In addition to IBM and Quest Diagnostics, our international investor base includes New York Life, Perseus-Soros BioPharmaceutical Fund LP, INVESCO Capital Management, Deutsche Vermogensbildungsgesellshaft m.b.H., Veritas SG Investment Trust GmbH, Castle Rock Capital Management of New York, New Medical Technologies, Dansk Kapitalanlæg A/S, BioAsia Investments, Vertex Venture Group (Singapore), and Swiss Capital Partners, among others.